VEG111485: A Phase I, Randomized, Double-Blinded, Placebo- Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on Cardiac Conduction in Subjects With Solid Tumors.

Trial Profile

VEG111485: A Phase I, Randomized, Double-Blinded, Placebo- Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on Cardiac Conduction in Subjects With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2011

At a glance

  • Drugs Moxifloxacin; Pazopanib
  • Indications Bacterial infections; Solid tumours
  • Focus Pharmacodynamics
  • Most Recent Events

    • 06 Apr 2010 Actual patient number (96) added, actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 06 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Aug 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top